New Test Targets Deadly Toxin After Infant Formula Scare

LYON, France – March 11, 2026 – In a significant move to bolster public health defenses, European diagnostics leader Eurofins Biomnis has launched a highly sensitive new test to detect the potent cereulide toxin in human stool samples. The announcement comes on the heels of a widespread public health scare in late 2025 and early 2026 that saw major infant formula brands recalled globally due to contamination with the dangerous substance, highlighting a critical gap in clinical diagnostic capabilities.

The new method, which uses advanced liquid chromatography tandem mass spectrometry (LC-MS/MS), provides clinicians with a vital tool to quickly and accurately identify cereulide exposure in patients. This development directly addresses urgent calls from medical bodies, including the French Society of Pediatrics, for more reliable analytical tools to investigate suspected foodborne intoxications, particularly in vulnerable populations like infants.

A Response to a Brewing Public Health Crisis

The need for such a test was thrown into sharp relief by a series of events that began in December 2025. Precautionary recalls for various infant and follow-on formula products from major manufacturers, including Nestlé and Danone, were issued across Europe and beyond. The contamination was eventually traced to a single raw ingredient used by multiple producers: arachidonic acid (ARA) oil, an omega-6 fatty acid produced through fermentation. This unexpected source revealed a structural vulnerability in the global food supply chain.

While many recalls were precautionary, the European Centre for Disease Prevention and Control (ECDC) reported a number of infant illnesses potentially linked to the contaminated products. The UK Health Security Agency investigated dozens of cases with symptoms consistent with cereulide poisoning. The incidents prompted swift action from regulatory bodies, with the European Food Safety Authority (EFSA) issuing urgent scientific advice in February 2026. EFSA established a new Acute Reference Dose (ARfD) for cereulide in infants at a stringent 0.014 micrograms per kilogram of body weight, underscoring the toxin's high potency.

Cereulide is far more dangerous than the typical bacteria that cause food poisoning. While most cases result in rapid-onset vomiting and nausea that resolve within 24 hours, high concentrations can be devastating. The toxin is known to cause severe liver damage, pancreatic dysfunction, and multi-organ failure. Infants and immunocompromised individuals are especially susceptible to these life-threatening complications, making early and accurate diagnosis paramount.

Bridging a Critical Diagnostic Gap

Until now, confirming a case of cereulide intoxication has been a major challenge for healthcare providers. The symptoms often mimic more common viral gastrointestinal illnesses, and as the ECDC noted in a recent assessment, testing for the toxin in clinical samples was not routinely available in most medical settings. This diagnostic void often left clinicians relying on symptom presentation and epidemiological links, creating uncertainty and potentially delaying appropriate patient management.

Eurofins Biomnis's new test is designed to fill this void. By providing a validated method for detecting and quantifying the toxin directly from a patient's stool sample, it offers a definitive way to confirm exposure. The company, which has roots stretching back to 1897, stated that the test has been fully validated according to the rigorous ISO 15189 standard for medical laboratories, ensuring its reliability and accuracy.

Crucially, the diagnostics provider ensures that the test's turnaround times are compatible with the demands of routine medical practice. This allows healthcare professionals to receive timely, scientifically robust results, enabling them to move past diagnostic uncertainty and make more informed decisions about treatment and patient care. For an infant suffering from dehydration and metabolic imbalances caused by the toxin, this speed can be critical.

The Science Behind the Silent Threat

The cereulide toxin is produced by specific strains of the bacterium Bacillus cereus, a microbe found almost everywhere in the environment, from soil to a wide array of food products like rice, pasta, and dairy. The bacterium's spores can survive pasteurization and other heat treatments, germinating and producing the toxin when food is stored at improper temperatures.

What makes cereulide particularly insidious is its extreme stability. It is resistant to heat, acid, and even microwave cooking. Once it has formed in a food product, it cannot be inactivated by normal cooking processes. This resilience means that even if the Bacillus cereus bacteria are killed, the pre-formed toxin remains active and dangerous.

At a cellular level, cereulide acts as a potent ionophore, specifically targeting the mitochondria—the powerhouses of our cells. It punches holes in the mitochondrial membrane, causing a collapse in cellular energy production. This mitochondrial dysfunction is the root cause of the severe organ damage seen in serious intoxication cases, from the liver to the brain.

Navigating the Path to Clinical Certainty

While the new LC-MS/MS test represents a breakthrough in detection, the company acknowledges a remaining challenge in the medical field: the absence of widely standardized clinical reference thresholds for interpreting cereulide concentrations in stool. In simple terms, while the test can tell a doctor how much toxin is present, there is not yet a universal consensus on what specific concentration level correlates with mild, moderate, or severe illness.

However, the launch of this quantitative test is a crucial first step toward establishing those very thresholds. By enabling the systematic collection of data linking cereulide levels in patients to clinical outcomes, this new tool will help the medical and scientific communities build the knowledge base needed for more nuanced interpretation. The recent ARfD established by EFSA for food provides a toxicological anchor that will inform these future clinical guidelines.

This innovation is not merely a technical achievement; it is a direct response to a clear and present need articulated by the medical community. The February 2026 recommendations from the French Society of Pediatrics, calling for such tools in the wake of the infant formula crisis, underscore the demand from frontline clinicians for better ways to protect their patients. By putting this powerful analytical method into the hands of doctors and laboratories, Eurofins Biomnis is providing an essential piece of the puzzle in the ongoing effort to manage and mitigate the risks of foodborne toxins.